QbD-based co-loading of paclitaxel and imatinib mesylate by protamine-coated PLGA nanoparticles effective on breast cancer cells. [PDF]
Nanomedicine (Lond)Laxane N, Yadav KS.
europepmc +1 more source
Use of a pH-responsive imatinib mesylate sustained-release hydrogel for the treatment of tendon adhesion by inhibiting PDGFRβ/CLDN1 pathway. [PDF]
Bioact MaterPang S +9 more
europepmc +1 more source
Safety outcomes of low versus high dose imatinib mesylate in patients with advanced, metastatic, or nonresectable gastrointestinal stromal tumors: A systematic review. [PDF]
Gastrointest TractMarucci MA, Lechner DW, Tafuto BA.
europepmc +1 more source
A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients. [PDF]
PLoS OneZeng L, Cheng X, Li J, Zhang J, Wu X.
europepmc +1 more source
Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance. [PDF]
Cancers (Basel)Boichuk S +3 more
europepmc +1 more source
Related searches:
Imatinib mesylate (imatinib) is an orally administered competitive inhibitor of the tyrosine kinases associated with the KIT protein (stem cell factor receptor), ABL protein and platelet-derived growth factor receptors. The KIT tyrosine kinase is abnormally expressed in gastrointestinal stromal tumour (GIST), a rare neoplasm for which there has been no
Monique P Curran +2 more
+22 more sources
Imatinib is an example of a new group of drugs being developed using the principle of molecular targeting. Imatinib is able to kill the cancer cells and not the body's healthy cells. Imatinib mesylate is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors and ...
Kathy Wilkinson, Monica P. Davey
+12 more sources
Another Look at Imatinib Mesylate
New England Journal of Medicine, 2006Imatinib mesylate may affect particular signaling pathways that increase susceptibility to congestive heart failure.
Klaus Strebhardt, Axel Ullrich
exaly +4 more sources
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Badraddin M H, Al-Hadiya +2 more
openaire +2 more sources